Searched for
BIOCON GENERICS INC.
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...- S&P Global upgrades Biocon Biologics credit rating To 'BB+'Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' wi...
- Biocon Q2 Results: Profit soars 428% YoY to Rs 85 crore on strong biosimilar and generics growthBiocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and g...
- Biocon inaugurates first manufacturing facility in USBiocon Ltd has inaugurated its first US manufacturing facility in Cranbury, New Jersey, operated by its subsidiary, Biocon Generics Inc. Fo...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the USBiocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...
- Stocks in news: IDFC First Bank, Kotak Mahindra Bank, IDBI Bank, Shaily Engineering, RVNLGMR Smart Electricity Distribution, a step down subsidiary of GMR Power and Urban Infra, has received a letter of award (LOA) from Purvanch...
- Biocon acquires Eywa Pharma's US-based plant for $7.7 millionBiocon Limited announced that its wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufact...
- On track to integrate major part of Viatris'' acquired biosimilars biz this fiscal: Kiran Mazumdar-ShawBiocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...
- Viatris buys Taparias' eyecare business for Rs 2,460 croreThe ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed f...
- Will Biocon's foray into biosimilar boost its bottomline?Biological drugs are harvested from living organisms or certain components of living organisms. These drugs are very specific and highly ef...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- Biocon Q4 results: Net profit grows 105% on strong biosimilar business growthFor the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 ...
- Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson add...
- Budget 2016: Regulations in pharma sector archaic, streamlining needed to stand up to competition, says Biocon's Kiran Mazumdar Shaw"This time around, India Inc should not expect any sop from the government because this is a budget that will focus on getting things right...
- Roche sues Biocon, Mylan, DCGI over breast cancer drugRoche has sued Mylan, Biocon for launching biosimilar version of the original breast cancer drug, Herceptin, and DCGI for allowing the laun...
- Pfizer ends supply deal with Claris LifesciencesMultinational drug-maker Pfizer Inc has terminated its three-year old supply deal with Claris Lifesciences, immediately after a ban on the ...
- Biocon-Mylan partnership has a potential of $33 billion from biosimilar drugsTwo years after announcing a JV with Mylan, Biocon has revealed the potential of its drugs under the biologics deal with Mylan.
- Pfizer scraps Insulin pact with BioconPfizer Inc has terminated a deal to sell Biocon's insulin products globally, dealing the Indian company a blow and calling into question si...
- Biocon picks up 70% in German pharma co AxiCorp for e30 mnThe deal will enable the Bangalore-based player to market its injectible insulin, generics, biosimilars and biologics in Europe.
Load More
